Single-use Bioreactors Market - Databook 2025 to 2034

The global single-use bioreactors market size was calculated at USD 4.92 billion in 2024 and is predicted to attain around USD 21.34 billion by 2034, expanding at a CAGR of 15.8% from 2025 to 2034.

Highlights of the Single-Use Bioreactors Market

• By region, North America dominated the global market revenue in 2024.
• By region, Asia Pacific is anticipated to grow at the fastest rate in the market during the forecast period.
• By product, the single-use bioreactor systems segment dominated the U.S. single-use bioreactors market in 2024.
• By product, the single-use filtration assemblies segment is expected to grow at the fastest rate in the market during the forecast period of 2025 to 2034.
• By type, the stirred-tank SUBs segment accounted for a considerable share of the market in 2024.
• By type, the wave-induced SUBs segment is projected to experience the highest growth rate in the market between 2025 and 2034.
• By type of cell, the mammalian cells segment dominated the market in 2024.
• By type of cell, the bacterial cells segment is set to experience the fastest rate of market growth from 2025 to 2034.
• By molecule type, the vaccines segment dominated the market in 2024.
• By molecule type, the gene-modified cells segment is anticipated to grow with the highest CAGR in the market during the studied years.
• By application, the research and development (R&D) or process development segment dominated the market in 2024.
• By application, the bioproduction segment dominated the market.
• By end-use, the CROs & CMOs segment maintained a leading position in the market in 2024.
• By end-use, the pharmaceutical & biopharmaceutical companies segment is projected to expand rapidly in the market in the coming years.
• By usage type, the pilot-scale production segment dominated the market in 2024.
• By usage type, the lab-scale production segment will gain a significant share of the market over the studied period of 2025 to 2034.

Industry Valuation and Growth Rate Projection

The single-use bioreactors market refers to a single-use bioreactor or disposable bioreactor, which can only be used once before being removed. It consists of a disposable bag instead of a traditional reusable culture vessel. They are applied in several areas, including cell and gene therapy, the production of monoclonal antibodies, vaccines, and T-cell-based therapeutics.

Some of the advantages of these bioreactors that set SUBs apart from conventional bioreactors are the reduced risk of batch contamination and cross-contamination, low operating costs, and supporting diverse manufacturing processes. SUBs facilitate the creation of bioartificial kidneys to replace or accompany dialysis. 

• Over 2 million people receive treatment for end-stage renal disease (ESRD) on a global scale, according to a study done by Roy, Fissell, and colleagues.

Single-Use Bioreactors Market: Stats and Figures

• As per the WHO, modern health systems are responsible for approximately 5% of global carbon emissions.
• The Tamil Nadu Public Works Department (PWD) proposes to install Sewage Treatment Plants (STPs) and Effluent Treatment Plants (ETPs) in 13 government hospitals in Chennai, India.
• In 2023, over 260 single-use bioreactors have been developed by more than 60 industry investors to allow the production of biologics. 
• In 2023, following the U.S. Food and Drug Administration, the quantity of single-use bioreactors installed in the US biopharma sector was counted to be 1,250.

Industry Leader Announcements

•  Chris Chen, PhD, CEO at WuXi Biologics:

Talking about how single-use bioreactors take over the stainless-steel systems, Chen said, “Over the past six years, by leveraging continuous process innovation, the company has applied SUT manufacturing in over 300 batches of scaled production ranging from 4,000 L to 16,000 L across multiple facilities, achieving a 99% production success rate over the past three years. Single-use technology manufacturing can attain COGs comparable to stainless-steel systems, while being the more eco-friendly approach, and it provides clients with greater flexibility and a wider range of options for patients worldwide.”

How AI Has Benefitted the Single-Use Bioreactors Market

• The single-use bioreactors market, alongside AI, shows a potential for changing the way SUBs work. Some of the many benefits AI provides are as follows:
• Rapid manufacturing: AI can speed up the development of biopharmaceutical manufacturing through research.
• Real-time monitoring: AI algorithms can constantly supervise dynamics like temperature and pH to improve the environment through real-time adjustments.
• Use in cell therapy: AI can accelerate the formulation of new cell therapies and improve cell sustainability.
• Data analysis: AI, using one of its commonly known properties, i.e., data study, can analyze vast amounts of data generated by bioreactors to gain insights.

Recent Developments:

• In 2024, GBI Biomanufacturing and Allterum Therapeutics joined hands to develop a monoclonal antibody (mAb) therapy in clinical trials for patients with acute lymphoblastic leukemia (ALL).
• In 2024, Culture Biosciences collaborated deliberately with Google Cloud to put money into cloud computing infrastructure and artificial intelligence tools mutually.

Geographical Insights 

The global single-use bioreactors market is experiencing significant growth, with North America maintaining its position as the dominant region while APAC emerges as the fastest-growing market. The European region keeps moving forward, too.

North America

The market in North America is considered to be the forerunner, given that big pharma firms are supporting the other companies in bringing treatment via bioreactors modestly in the region.

 Thermo Fisher Scientific has familiarized the 5L DynaDrive single-use bioreactor, so the requisites of CDMOs, biopharma companies, and small biotechnology companies can be taken care of.

Europe

The European market is growing swiftly, owing to the biotech firms introducing bioreactors with innovative technologies in the region.

The company Celonic, not long ago, launched a new Biologics Development Center with the objective of building processes through perfusion technology.

APAC

The single-use bioreactors market in the APAC region is developing at a quicker pace as a consequence of the countries putting their best foot forward to achieve the goal of a reduced carbon footprint.

The countries within the APAC boundaries, like Japan, China, and India, are taking up practices, net-zero emission targets for 2050, Blue Sky, and draft rules to limit antibiotic discharge, respectively, so that the challenges of climate change, leading to global warming, can be toned down.

Competitive Landscape 

The single-use bioreactors market is highly competitive, with leading bioengineering companies such as Thermo Fisher Scientific, Merck KGaA, Danaher Corporation, GE HealthCare, Eppendorf AG, Applikon Biotechnology B.V., PBS Biotech, Inc., and CESCO Bioengineering Co., Ltd. holding the highest market share. Emerging biotech firms also play a crucial role by fostering a dynamic and evolving competitive landscape.

The market is dominated by several bioengineering companies renowned for their significant contributions to cancer research and treatment. Based on recent data, the top three leading companies are:

• Company Name: Thermo Fisher Scientific
• Year of Incorporation: 1956
• Headquarters: Massachusetts, United States

The yearly revenue of Thermo Fisher Scientific was accounted to be $42,879,000 in 2024.

• Company Name: Merck KGaA
• Year of Incorporation: 1668
• Headquarters: Darmstadt, Germany

The annual revenue of Merck KGaA leaped from $20,993,000 in 2023 to $21,156,000 in 2024.

• Company Name: Danaher Corporation
• Year of Incorporation: 1986
• Headquarters: Washington, D.C., United States

The gross profit of Danaher Corporation stood at $14,206,000 in 2024.